Phase I study of FK 435

O. Abe, K. Enomoto, K. Fujiwara, M. Izuo, Y. Iino, T. Tominaga, K. Hayashi, O. Takatani, N. Kugai, M. Yoshida

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We performed phase I study of FK 435, a new antiestrogen, in 30 patients with advanced breast cancer. Slight to moderate adverse reactions were noted as follows. Single-dose study: anorexia, nausea, lassitude in one patient (80 mg), decreased serum calcium in one (160 mg), redness, tenderness in one, facial flushing, hot flushes, headache in one (320 mg). Repeated-dose study: anorexia, nausea in one patient (40 mg/day), anorexia, diarrhea, increased FSH in one, increased PRL in one (80 mg/day). FK 435 was well tolerated. Tmax was 3-5 hours, T1/2 about 25 hours. Most of FK 435 was excreted into urine as glucuronide.

Original languageEnglish
Pages (from-to)903-913
Number of pages11
JournalGan no rinsho. Japan journal of cancer clinics
Volume36
Issue number8
Publication statusPublished - 1990 Jul

Fingerprint

Anorexia
Nausea
Estrogen Receptor Modulators
Glucuronides
Fatigue
Headache
Diarrhea
Urine
Breast Neoplasms
Calcium
Serum
droloxifene

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Abe, O., Enomoto, K., Fujiwara, K., Izuo, M., Iino, Y., Tominaga, T., ... Yoshida, M. (1990). Phase I study of FK 435. Gan no rinsho. Japan journal of cancer clinics, 36(8), 903-913.

Phase I study of FK 435. / Abe, O.; Enomoto, K.; Fujiwara, K.; Izuo, M.; Iino, Y.; Tominaga, T.; Hayashi, K.; Takatani, O.; Kugai, N.; Yoshida, M.

In: Gan no rinsho. Japan journal of cancer clinics, Vol. 36, No. 8, 07.1990, p. 903-913.

Research output: Contribution to journalArticle

Abe, O, Enomoto, K, Fujiwara, K, Izuo, M, Iino, Y, Tominaga, T, Hayashi, K, Takatani, O, Kugai, N & Yoshida, M 1990, 'Phase I study of FK 435', Gan no rinsho. Japan journal of cancer clinics, vol. 36, no. 8, pp. 903-913.
Abe O, Enomoto K, Fujiwara K, Izuo M, Iino Y, Tominaga T et al. Phase I study of FK 435. Gan no rinsho. Japan journal of cancer clinics. 1990 Jul;36(8):903-913.
Abe, O. ; Enomoto, K. ; Fujiwara, K. ; Izuo, M. ; Iino, Y. ; Tominaga, T. ; Hayashi, K. ; Takatani, O. ; Kugai, N. ; Yoshida, M. / Phase I study of FK 435. In: Gan no rinsho. Japan journal of cancer clinics. 1990 ; Vol. 36, No. 8. pp. 903-913.
@article{92bca6d4708149fc9be94ea55e94c0f1,
title = "Phase I study of FK 435",
abstract = "We performed phase I study of FK 435, a new antiestrogen, in 30 patients with advanced breast cancer. Slight to moderate adverse reactions were noted as follows. Single-dose study: anorexia, nausea, lassitude in one patient (80 mg), decreased serum calcium in one (160 mg), redness, tenderness in one, facial flushing, hot flushes, headache in one (320 mg). Repeated-dose study: anorexia, nausea in one patient (40 mg/day), anorexia, diarrhea, increased FSH in one, increased PRL in one (80 mg/day). FK 435 was well tolerated. Tmax was 3-5 hours, T1/2 about 25 hours. Most of FK 435 was excreted into urine as glucuronide.",
author = "O. Abe and K. Enomoto and K. Fujiwara and M. Izuo and Y. Iino and T. Tominaga and K. Hayashi and O. Takatani and N. Kugai and M. Yoshida",
year = "1990",
month = "7",
language = "English",
volume = "36",
pages = "903--913",
journal = "Gan no rinsho. Japan journal of cancer clinics",
issn = "0021-4949",
number = "8",

}

TY - JOUR

T1 - Phase I study of FK 435

AU - Abe, O.

AU - Enomoto, K.

AU - Fujiwara, K.

AU - Izuo, M.

AU - Iino, Y.

AU - Tominaga, T.

AU - Hayashi, K.

AU - Takatani, O.

AU - Kugai, N.

AU - Yoshida, M.

PY - 1990/7

Y1 - 1990/7

N2 - We performed phase I study of FK 435, a new antiestrogen, in 30 patients with advanced breast cancer. Slight to moderate adverse reactions were noted as follows. Single-dose study: anorexia, nausea, lassitude in one patient (80 mg), decreased serum calcium in one (160 mg), redness, tenderness in one, facial flushing, hot flushes, headache in one (320 mg). Repeated-dose study: anorexia, nausea in one patient (40 mg/day), anorexia, diarrhea, increased FSH in one, increased PRL in one (80 mg/day). FK 435 was well tolerated. Tmax was 3-5 hours, T1/2 about 25 hours. Most of FK 435 was excreted into urine as glucuronide.

AB - We performed phase I study of FK 435, a new antiestrogen, in 30 patients with advanced breast cancer. Slight to moderate adverse reactions were noted as follows. Single-dose study: anorexia, nausea, lassitude in one patient (80 mg), decreased serum calcium in one (160 mg), redness, tenderness in one, facial flushing, hot flushes, headache in one (320 mg). Repeated-dose study: anorexia, nausea in one patient (40 mg/day), anorexia, diarrhea, increased FSH in one, increased PRL in one (80 mg/day). FK 435 was well tolerated. Tmax was 3-5 hours, T1/2 about 25 hours. Most of FK 435 was excreted into urine as glucuronide.

UR - http://www.scopus.com/inward/record.url?scp=0025455806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025455806&partnerID=8YFLogxK

M3 - Article

C2 - 2195179

AN - SCOPUS:0025455806

VL - 36

SP - 903

EP - 913

JO - Gan no rinsho. Japan journal of cancer clinics

JF - Gan no rinsho. Japan journal of cancer clinics

SN - 0021-4949

IS - 8

ER -